BPC-157 vs TB-500: what is the difference and what are they used for

Important: This information is for educational and research purposes only. Research peptides are not approved for human consumption. Consult a qualified medical professional before any use.

BPC-157 and TB-500 are the two most discussed research peptides in the field of tissue regeneration. Both are studied in preclinical models for tendon, muscle, and wound healing — but their origin, mechanism of action, and research focus differ significantly.

In this guide we compare the two peptides based on peer-reviewed scientific sources, to help researchers understand which one is suited for what.

Origin and structure

BPC-157

BPC-157 (Body Protection Compound 157) is a 15-amino-acid peptide (pentadecapeptide) isolated from a protective protein in human gastric juice. Its sequence (GEPPPGKPADDAGLV) does not occur anywhere else in nature — it is a fragment of a larger molecule with a presumed cytoprotective function in the stomach.

It has been studied since 1991 by a Croatian team, mainly in preclinical models focused on tissue repair.

TB-500

TB-500 is a synthetic fragment of the naturally occurring peptide Thymosin Beta-4 (Tβ4) — a 43-amino-acid regulatory peptide present in all cells of the human body. TB-500 itself represents a shorter sequence (LKKTETQ, positions 17-23 of Tβ4) — the active actin-binding motif.

Thymosin Beta-4 was isolated back in 1981 and has been studied in multiple contexts — wound healing, cardiac muscle regeneration, immune modulation.

Mechanism of action

This is the most important distinction between the two peptides — they work through different biochemical pathways.

BPC-157

BPC-157 exhibits a pleiotropic effect through several intertwining mechanisms:

• Angiogenesis — stimulates the formation of new blood vessels by modulating VEGF (Vascular Endothelial Growth Factor) in the injury site
• Nitric Oxide (NO) signaling — interacts with the eNOS/NO pathway, which explains its vasodilatory effects and improved perfusion
• FAK-paxillin activation — associated with cell migration and tissue repair, especially in tendons
• Growth hormone receptor — review articles show increased GH receptor expression in the sites of action

TB-500

TB-500 has a more specific mechanism — sequestration of G-actin (monomeric actin). By binding G-actin, the peptide regulates actin polymerization dynamics — a critical process for:

• Cell migration (fibroblasts, keratinocytes, endothelial cells move toward the site of injury)
• Extracellular matrix remodeling
• Wound closure

Simply put: BPC-157 works locally and multimodally, while TB-500 acts systemically and through one primary mechanism.

Scientific research — what we actually know

BPC-157: preclinical evidence

A systematic review from 2025 in HSS Journal analyzed 36 studies on BPC-157, of which 35 preclinical (animal) and only 1 clinical. In preclinical models BPC-157 shows:

• Improved healing of muscles, tendons, ligaments, and bones
• Functional, structural, and biomechanical improvements
• Reduced inflammatory cytokines

Limitation: Human clinical evidence remains minimal. The FDA classified BPC-157 as a Category 2 bulk drug substance in 2023 — meaning insufficient evidence of safety in humans.

TB-500: preclinical evidence

Studies on Thymosin Beta-4 (from which TB-500 is derived) show:

• Accelerated dermal healing by 42-61% in animal models over 4-7 days after treatment
• Increased re-epithelialization
• Increased collagen deposition and angiogenesis in treated wounds
• Minimal scarring in incisional wounds

Clinical evidence: Two Phase 2 clinical trials for stasis and pressure ulcers showed accelerated healing by almost a month in patients who healed. This is more advanced human evidence than for BPC-157.

Research focus

| Criterion | BPC-157 | TB-500 |
|---|---|---|
| Main focus | Tendons, ligaments, GI tract | Wounds, skin, cardiac muscle |
| Type of action | Local, multimodal | Systemic, actin-based |
| Preclinical evidence | Very strong | Very strong |
| Clinical evidence | Minimal | Limited (Phase 2) |
| Number of amino acids | 15 (pentadecapeptide) | 7 (fragment) / 43 (full Tβ4) |

Which one is studied for what?

Important — the following describes research applications in preclinical models, not medical recommendations.

BPC-157 is primarily studied for:

• Tendon-bone healing
• Muscle injuries
• Inflammatory diseases of the GI tract
• Neuroprotection (emerging research)

TB-500 is primarily studied for:

• Wound healing (incl. diabetic ulcers)
• Dermal regeneration
• Cardiac regeneration after infarction
• Postoperative recovery

Combined use ("Wolverine stack")

In research communities, combining the two peptides is discussed — the so-called "Wolverine stack". The theoretical rationale: the different mechanisms may be complementary (BPC-157 for angiogenesis + local action, TB-500 for systemic cell migration).

However, there is no peer-reviewed clinical evidence for combined use in humans. Any research on stack-based protocols exists only in preclinical models or informal research reports.

Quality and sources

Both peptides are widely offered as research-grade. When choosing a supplier, be sure to check:

• HPLC purity ≥98% (confirmed by Certificate of Analysis)
• Mass Spectrometry confirmation of molecular mass
• Batch number for traceability
• Thermally insulated delivery with cold chain

Read our full guide on how to recognize quality peptides and the complete peptide guide.

Legal and regulatory status

In the EU context:

• Neither BPC-157 nor TB-500 is approved by the EMA for medical use
• They are offered only as research chemicals for qualified laboratories and research institutions
• They are not authorized for human consumption, dietary supplements, or cosmetics
• As of June 1, 2026, the new EMA directive on synthetic peptides is in effect, setting strict manufacturing standards

WADA (World Anti-Doping Agency) has classified both peptides on the prohibited list for professional athletes.

Summary

BPC-157 and TB-500 share similar therapeutic themes (tissue regeneration), but work through different mechanisms and have different research focuses.

• BPC-157 — multi-mechanism, musculoskeletal focus, less clinical evidence
• TB-500 — actin-based systemic effect, broader focus on wounds and skin, slightly more clinical evidence

The choice between the two for research purposes depends on the specific experiment. For both, human clinical data remain limited — future years should bring more randomized controlled trials before conclusions about clinical applicability can be drawn.

Scientific sources

1. Vasireddi N. et al. (2025). Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal.
2. Seiwerth S. et al. (2025). Multifunctionality and Possible Medical Application of the BPC 157 Peptide — Literature and Patent Review. Pharmaceuticals (Basel).
3. Chang C.H. et al. (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing. Journal of Applied Physiology.
4. Malinda K.M. et al. (1999). Thymosin beta4 accelerates wound healing. Journal of Investigative Dermatology.
5. Crockford D. et al. (2010). Thymosin β4: structure, function, and biological properties. Annals of NY Academy of Sciences.
6. Philp D. et al. (2013). The regenerative peptide thymosin β4 accelerates the rate of dermal healing in preclinical animal models and in patients.